
Remepy
Remepy
Remepy
Pioneering hybrid drugs
Pioneering hybrid drugs
Pioneering hybrid drugs
Biotechnology Research
Biotechnology Research
⋅
⋅
New York
New York
US
US
⋅
⋅
51–200 employees
51–200 employees
⋅
⋅
Founded:
Founded:
January 2022
January 2022
Overview
Overview
Remepy is Pioneering Hybrid Drugs™.
Many medical conditions are better treated by combining pharmaceutical and non-pharmaceutical treatments. Hybrid drugs are a new type of drug asset, that combines traditional drugs with proprietary treatment protocols delivered measured and adapted using our AI capabilities.
Remepy’s Digital Molecules™ are designed to be the software apps within Hybrid Drugs™. They are based on digital interventions and treatment protocols that are tailored to each medical condition and its corresponding drug and are constantly measured and tracked and personalized using advanced AI capabilities.
The Digital Molecules™ enhance brain functions that balance the patient's neuro-endocrine and neuro-immunological systems and boost brain neuroplasticity, in order to optimize drug performance. We also address physical, motor, psychological, and behavioral symptoms
Remepy partners with pharma companies to bring Hybrid Drugs™ to market that will combine Remepy’s Digital Molecule™ and traditional drug components.
Remepy is Pioneering Hybrid Drugs™.
Many medical conditions are better treated by combining pharmaceutical and non-pharmaceutical treatments. Hybrid drugs are a new type of drug asset, that combines traditional drugs with proprietary treatment protocols delivered measured and adapted using our AI capabilities.
Remepy’s Digital Molecules™ are designed to be the software apps within Hybrid Drugs™. They are based on digital interventions and treatment protocols that are tailored to each medical condition and its corresponding drug and are constantly measured and tracked and personalized using advanced AI capabilities.
The Digital Molecules™ enhance brain functions that balance the patient's neuro-endocrine and neuro-immunological systems and boost brain neuroplasticity, in order to optimize drug performance. We also address physical, motor, psychological, and behavioral symptoms
Remepy partners with pharma companies to bring Hybrid Drugs™ to market that will combine Remepy’s Digital Molecule™ and traditional drug components.
Founder
Founder

Or Shoval
Or Shoval
Co-Founder & Co-CEO at Remepy
Co-Founder & Co-CEO at Remepy
Employee Growth
Employee Growth
TOTAL EMPLOYEES
TOTAL EMPLOYEES
89
89
6m GROWTH
6m GROWTH
22%
22%
1y GROWTH
1y GROWTH
46%
46%
Department Distribution
Department Distribution
TOTAL EMPLOYEES
TOTAL EMPLOYEES
89
89
Engineering
Engineering
Program and Project Management
Program and Project Management
Arts and Design
Arts and Design
Entrepreneurship
Entrepreneurship
Business Development
Business Development
Department Growth
Department Growth
6m GROWTH
6m GROWTH
1y GROWTH
1y GROWTH
Engineering
20%
33%
Program and Project Management
80%
200%
Arts and Design
33%
167%
Entrepreneurship
14%
14%
Business Development
0%
-12%
Web Engagement
pages per visit
pages per visit
2.5
2.5
monthly visits
monthly visits
6,207
6,207
Web Traffic by Country
Web Traffic by Country
Israel
68.7%
Israel
68.7%
United States
31.3%
United States
31.3%
Web Traffic Sources
Web Traffic Sources
Direct
30.3%
Direct
30.3%
Search
37.8%
Search
37.8%
Social
6.8%
Social
6.8%
Referrals
9.5%
Referrals
9.5%
AI
2.3%
AI
2.3%
funding round
2
total funding raised
$62M
last round type
Series A
last round amount
$36M
announced on
$36M
funding round
2
total funding raised
$62M
last round type
Series A
last round amount
$36M
announced on
$36M
lead investors
lead investors
O.G. Venture Partners, M Ventures, NFX, Vine Ventures, Qumra Capital, TechAviv, 97212 Ventures, Fresh Fund, PsyMed Ventures, Tadmor Group, Key1 Capital, IT-Farm Corp
O.G. Venture Partners, M Ventures, NFX, Vine Ventures, Qumra Capital, TechAviv, 97212 Ventures, Fresh Fund, PsyMed Ventures, Tadmor Group, Key1 Capital, IT-Farm Corp
Recent News & Articles
Recent News & Articles

A network graph of your entire TAM. We find the path into every account worth a meeting, and book it.
A network graph of your entire TAM. We find the path into every account worth a meeting, and book it.


© 2026 InGrow. All rights reserved.
© 2026 InGrow. All rights reserved.


